154 related articles for article (PubMed ID: 25140053)
1. The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility.
Kiuchi T; Ortiz-Zapater E; Monypenny J; Matthews DR; Nguyen LK; Barbeau J; Coban O; Lawler K; Burford B; Rolfe DJ; de Rinaldis E; Dafou D; Simpson MA; Woodman N; Pinder S; Gillett CE; Devauges V; Poland SP; Fruhwirth G; Marra P; Boersma YL; Plückthun A; Gullick WJ; Yarden Y; Santis G; Winn M; Kholodenko BN; Martin-Fernandez ML; Parker P; Tutt A; Ameer-Beg SM; Ng T
Sci Signal; 2014 Aug; 7(339):ra78. PubMed ID: 25140053
[TBL] [Abstract][Full Text] [Related]
2. ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo.
Muraoka-Cook RS; Sandahl MA; Strunk KE; Miraglia LC; Husted C; Hunter DM; Elenius K; Chodosh LA; Earp HS
Mol Cell Biol; 2009 Sep; 29(18):4935-48. PubMed ID: 19596786
[TBL] [Abstract][Full Text] [Related]
3. HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling.
Hartman Z; Zhao H; Agazie YM
Oncogene; 2013 Aug; 32(35):4169-80. PubMed ID: 23027125
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients.
Machleidt A; Buchholz S; Diermeier-Daucher S; Zeman F; Ortmann O; Brockhoff G
BMC Cancer; 2013 Sep; 13():437. PubMed ID: 24063248
[TBL] [Abstract][Full Text] [Related]
5. Threshold-controlled ubiquitination of the EGFR directs receptor fate.
Sigismund S; Algisi V; Nappo G; Conte A; Pascolutti R; Cuomo A; Bonaldi T; Argenzio E; Verhoef LG; Maspero E; Bianchi F; Capuani F; Ciliberto A; Polo S; Di Fiore PP
EMBO J; 2013 Jul; 32(15):2140-57. PubMed ID: 23799367
[TBL] [Abstract][Full Text] [Related]
6. The adaptor proteins p66Shc and Grb2 regulate the activation of the GTPases ARF1 and ARF6 in invasive breast cancer cells.
Haines E; Saucier C; Claing A
J Biol Chem; 2014 Feb; 289(9):5687-703. PubMed ID: 24407288
[TBL] [Abstract][Full Text] [Related]
7. Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration.
Haskins JW; Nguyen DX; Stern DF
Sci Signal; 2014 Dec; 7(355):ra116. PubMed ID: 25492965
[TBL] [Abstract][Full Text] [Related]
8. Cbl and Itch binding sites in ERBB4 CYT-1 and CYT-2 mediate K48- and K63-polyubiquitination, respectively.
Meijer IM; van Rotterdam W; van Zoelen EJ; van Leeuwen JE
Cell Signal; 2013 Feb; 25(2):470-8. PubMed ID: 23153581
[TBL] [Abstract][Full Text] [Related]
9. ErbB2 and ErbB4 Cbl binding sites can functionally replace the ErbB1 Cbl binding site.
Jansen SM; Sleumer LS; Damen E; Meijer IM; van Zoelen EJ; van Leeuwen JE
Cell Signal; 2009 May; 21(5):810-8. PubMed ID: 19263517
[TBL] [Abstract][Full Text] [Related]
10. Negative regulation of EGFR-Vav2 signaling axis by Cbl ubiquitin ligase controls EGF receptor-mediated epithelial cell adherens junction dynamics and cell migration.
Duan L; Raja SM; Chen G; Virmani S; Williams SH; Clubb RJ; Mukhopadhyay C; Rainey MA; Ying G; Dimri M; Chen J; Reddi AL; Naramura M; Band V; Band H
J Biol Chem; 2011 Jan; 286(1):620-33. PubMed ID: 20940296
[TBL] [Abstract][Full Text] [Related]
11. Flotillin-2 regulates epidermal growth factor receptor activation, degradation by Cbl-mediated ubiquitination, and cancer growth.
Wisniewski DJ; Liyasova MS; Korrapati S; Zhang X; Ratnayake S; Chen Q; Gilbert SF; Catalano A; Voeller D; Meerzaman D; Guha U; Porat-Shliom N; Annunziata CM; Lipkowitz S
J Biol Chem; 2023 Jan; 299(1):102766. PubMed ID: 36470425
[TBL] [Abstract][Full Text] [Related]
12. WW domain containing E3 ubiquitin protein ligase 1 targets the full-length ErbB4 for ubiquitin-mediated degradation in breast cancer.
Li Y; Zhou Z; Alimandi M; Chen C
Oncogene; 2009 Aug; 28(33):2948-58. PubMed ID: 19561640
[TBL] [Abstract][Full Text] [Related]
13. CTEN prolongs signaling by EGFR through reducing its ligand-induced degradation.
Hong SY; Shih YP; Li T; Carraway KL; Lo SH
Cancer Res; 2013 Aug; 73(16):5266-76. PubMed ID: 23774213
[TBL] [Abstract][Full Text] [Related]
14. The E3 ubiquitin ligase WWP1 selectively targets HER4 and its proteolytically derived signaling isoforms for degradation.
Feng SM; Muraoka-Cook RS; Hunter D; Sandahl MA; Caskey LS; Miyazawa K; Atfi A; Earp HS
Mol Cell Biol; 2009 Feb; 29(3):892-906. PubMed ID: 19047365
[TBL] [Abstract][Full Text] [Related]
15. ErbB4 expression in neural progenitor cells (ST14A) is necessary to mediate neuregulin-1beta1-induced migration.
Gambarotta G; Garzotto D; Destro E; Mautino B; Giampietro C; Cutrupi S; Dati C; Cattaneo E; Fasolo A; Perroteau I
J Biol Chem; 2004 Nov; 279(47):48808-16. PubMed ID: 15355992
[TBL] [Abstract][Full Text] [Related]
16. E3 ligase-inactivation rewires CBL interactome to elicit oncogenesis by hijacking RTK-CBL-CIN85 axis.
Ahmed SF; Buetow L; Gabrielsen M; Lilla S; Sibbet GJ; Sumpton D; Zanivan S; Hedley A; Clark W; Huang DT
Oncogene; 2021 Mar; 40(12):2149-2164. PubMed ID: 33627783
[TBL] [Abstract][Full Text] [Related]
17. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
Canfield K; Li J; Wilkins OM; Morrison MM; Ung M; Wells W; Williams CR; Liby KT; Vullhorst D; Buonanno A; Hu H; Schiff R; Cook RS; Kurokawa M
Cell Cycle; 2015; 14(4):648-55. PubMed ID: 25590338
[TBL] [Abstract][Full Text] [Related]
18. Suppressed expression of Cbl-b by NF-κB mediates icotinib resistance in EGFR-mutant non-small-cell lung cancer.
Zhang T; Zheng C; Hou K; Wang J; Zhang Y; Fan Y; Zhao H; Qu X; Liu Y; Kang J; Che X; Hu X
Cell Biol Int; 2019 Feb; 43(2):98-107. PubMed ID: 29972257
[TBL] [Abstract][Full Text] [Related]
19. Growth and motility inhibition of breast cancer cells by epidermal growth factor receptor degradation is correlated with inactivation of Cdc42.
Hirsch DS; Shen Y; Wu WJ
Cancer Res; 2006 Apr; 66(7):3523-30. PubMed ID: 16585176
[TBL] [Abstract][Full Text] [Related]
20. Keeping EGFR signaling in check: ubiquitin is the guardian.
Polo S; Di Fiore PP; Sigismund S
Cell Cycle; 2014; 13(5):681-2. PubMed ID: 24526125
[No Abstract] [Full Text] [Related]
[Next] [New Search]
